Clinical Trial Update: Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Melagatran/Ximelagatran with Enoxaparin for prevention of venous thromboembolism has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)
• Melagatran/Ximelagatran

Snippet

Sponsor: AstraZeneca | Conditions: Thromboembolism | Phase 3 | Status: TERMINATED